Tag: Medication recall

As of September 2025, the combined monophasic oral contraceptive Sprintec is not discontinued and remains widely available from its manufacturer, Teva Pharmaceuticals. The widespread confusion about its status stems from a 2024 recall and prior shortages related to its triphasic sibling, Tri-Lo-Sprintec.

In 2025, several over-the-counter (OTC) cold medications have been recalled for reasons ranging from contamination to packaging defects [1.2.4, 1.3.2]. This article details which cold medicine was recently recalled, the reasons why, and what consumers need to know to stay safe.

Recent drug shortage reports from health authorities like Health Canada indicate multiple betahistine products have experienced significant supply disruptions. Patients relying on this medication for conditions like Meniere's disease are facing challenges understanding why there is a shortage of betahistine and what steps they can take to manage their condition.

Before its market withdrawal in 2020, diarrhea was a recognized, though uncommon, side effect associated with ranitidine use. The medication, once widely known under the brand name Zantac, was prescribed for conditions like GERD and ulcers. Its removal from shelves, however, was prompted by a more serious discovery regarding potential cancer-causing impurities.

In 2020, the U.S. Food and Drug Administration (FDA) requested the removal of all ranitidine products, widely known by the brand name **Zantac**, from the market due to unacceptable levels of a probable carcinogen. This critical action underscored a major distinction between it and other stomach medications, raising the important question: **is sucralfate the same as zantac?** The answer is a definitive no, and understanding their different approaches to treating gastrointestinal issues is crucial for patient safety and effective treatment.

In May 2025, over 235,000 Airsupra inhaler canisters were recalled nationwide [1.2.2]. This guide answers the critical question for patients with asthma and COPD: which inhalers are being recalled and what steps should you take to ensure your treatment is safe?

In September 2024, over 3 million tubes of Refresh P.M. and Refresh Lacri-Lube lubricant eye ointments were recalled due to a tube seal issue that could compromise sterility. Knowing which lots of Refresh PM were recalled is crucial for consumer safety, as is understanding the reasons behind these and past recalls, such as one in 2015.

Susvimo was first FDA-approved in October 2021 for wet age-related macular degeneration, but a voluntary recall in 2022 due to manufacturing issues created a temporary hurdle. Today, following a successful relaunch in 2024, Susvimo is not only FDA-approved but also carries multiple indications for treating serious retinal conditions.

In July 2000, following multiple reports of severe cardiac arrhythmias and fatalities, the GI motility drug Propulsid (cisapride) was voluntarily withdrawn from the U.S. market by its manufacturer. This action has led many to question, 'Can you still get Propulsid?', and the answer for most people is a definitive no.

As of September 2025, there are active recalls for specific batches of levothyroxine sodium tablets, with actions taken by manufacturers like Accord Healthcare and Pfizer. These recalls primarily cite subpotency, meaning the medication's active ingredient is below the labeled specification.